ABSTRACT
ObjectiveTo study the effect of Jinlida granules on visceral fat accumulation and its induced inflammatory response in prediabetic rats. MethodMale SD rats were randomly divided into normal group， model group， Jinlida low-dose group （1.5 g·kg-1）， Jinlida high-dose group （3.0 g·kg-1） and atorvastatin group （10 mg·kg-1）. Prediabetic rat model was established using high-carbohydrate， high-fat diet combined with low-dose streptozotocin （STZ） by multiple small-dose intraperitoneal injections. After 8 weeks of modeling and drug intervention for 13 consecutive weeks， body weight， oral glucose tolerance test（OGTT）， fasting blood glucose （FBG）， fasting insulin （FINS）， insulin resistance index （HOMA-IR）， total cholesterol （TC）， low-density lipoprotein cholesterol （LDL-C） and high-density lipoprotein cholesterol （HDL-C） were measured in each group of rats. The content of visceral fat was quantified by micro-computed tomography （Micro-CT）. Hematoxylin-eosin staining （HE） was used to observe the pathological changes of fat cells. The levels of tumor necrosis factor-α （TNF-α） and interleukin- 6 （IL-6） in rat visceral fat and serum were determined by enzyme linked immunosorbent assay （ELISA）. The expression of macrophage marker CD68 in visceral fat was detected by immunofluorescence and Western blot. ResultCompared with normal group， model group had increased oral glucose tolerance， FBG， FINS， HOMA-IR， TC， LDL-C （P<0.01）， elevated body weight and visceral fat accumulation （P<0.05， P<0.01）， enhanced CD68 protein expression and TNF-α and IL-6 levels （P<0.01）， decreased HDL-C （P<0.01）， and abnormal hypertrophy of adipocytes. Compared with model group， Jinlida high- and low-dose groups lowered oral glucose tolerance， HOMA-IR， TC and LDL-C （P<0.05， P<0.01）， body weight and visceral fat accumulation （P<0.05）， and CD68 protein expression and TNF-α and IL-6 levels （P<0.05， P<0.01） and lessened hypertrophy of fat cells. ConclusionJinlida can improve the insulin resistance in prediabetic rats by reducing visceral fat accumulation and its induced inflammatory response， which provides a new pharmacological basis for clinical treatment of prediabetes by Jinlida granules.
ABSTRACT
Objective To investigate the effect of Jinlida granules on blood glucose level, physiological index, and the nuclear factor-kappa B (NF-κB) pathway in mice. Methods Mice were randomly divided into a positive control group (acarbose group), an experimental group (Jinlida granule group), and a blank control group. The effects of Jinlida granules on blood glucose levels and weights of the mice were measured after single and multiple ingestion of sucrose or starch. The levels of superoxide dismutase and malondialdehyde were measured in mice via enzyme-linked immunosorbent assay. Changes in serum lipids and other indicators were detected using an automatic biochemical analyzer in order to determine the regulatory effect of Jinlida granules on blood lipid levels and liver and kidney damage. Changes in NF-κB, interleukin (IL) -1β, and IL-6 levels were detected via Western blotting. Results Jinlida granules downregulated postprandial blood glucose levels without reducing body weight in mice. Jinlida granules also reduced serum triglyceride concentration without causing damage to the liver or kidneys in mice, showed protective effects on muscle cells, and may reduce activation of the NF-κB pathway. Conclusion Jinlida granules may contribute to ameliorating diabetes.
ABSTRACT
Objective: To observe the clinical efficacy of Jinlida (JLD) granules and Tongxinluo (TXL) capsules on type 2 diabetic kidney disease (DKD) under the guidance of vessel collateral theory. Method: A total of 120 patients with type 2 DKD, were randomly divided into 2 groups:the normal control group (60 cases) and the treatment group (60 cases). The patients in normal control group were treated with dietary control and hyperglycemia control. Based on treatment in control group, patients in treatment group were additionally treated with JLD granules (1 bag, tid), and TXL capsules (4 capsules, tid). The treatment was lasted for 12 weeks. The clinical efficacy, traditional Chinese medicine(TCM) syndrome scores were observed and compared before and after treatment. At the same time, the levels of glucose metabolism indexes including fasting blood glucose (FBG),postprandial 2 h plasma glucose (2 hPG), glycosylated hemoglobin (HbA1c) and the insulin resistance (IR); the levels of lipid metabolism indexes including total cholesterol(TC),triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and the high-density lipoprotein cholesterol (HDL-C); the levels of renal function indexes including urinary albumin excretion rate (UAER) and serum creatinine (SCr); as well as nailfold microcirculation were detected and compared. Result: ①The total effective rate was 80.0% in treatment group, significantly higher than 61.67% in the normal control group (PPPPPβ2-MG in treatment group was significantly obvious than that in the control group (PPConclusion: Tongxinluo combined with Jinlida can improve the clinical symptoms of patients with type 2 diabetic nephropathy and reduce urinary trace albumin, and its mechanism may be related to lowering glucose, regulating lipid metabolism and improving microcirculation.
ABSTRACT
Objective:To study the curative efficacy of metformin combined with Jinlida granules in the treatment of gestational diabetes mellitus and its effects on the serum vascular endothelial growth factor (VEGF),adiponectin (APN) and homocysteine(Hcy) levels.Methods:94 patients of gestational diabetes mellitus who were treated from July 2014 to July 2016 in our hospital were selected.According to random number table,those patients were divided into the observation group (n=47) and the control group (n=47).On the basis of routine treatment,such as control diet,reasonable exercise and healthy diet,etc,the control group was treated with metformin,while the observation group was combined with Jinlida granules on the basis of the control group.The changes of blood glucose,blood lipid and serum VEGF,APN and Hcy before and after treatment were compared between the two groups,the incidence of maternal complications and neonatal adverse outcomes were compared.Results:Compared with before treatment,the blood glucose,blood lipid of both groups after treatment were significantly improved (P ＜0.05),the fasting plasma glucose (FBG),postprandial 2h blood glucose (2hPG),glycosylated hemoglobin (HbAlc),total cholesterol (TC),triacylglycerol (TG),low density lipoprotein cholesterol(LDL-C) of observation group were significantly lower than those of the control group,the serum high density lipoprotein cholesterol (HDL-C) level was significantly higher than that of the control group(P＜0.05);after treatment,the serum VEGF,APN and Hcy levels were significantly improved than those before treatment in both groups (P＜0.05),and the serum VEGF,and Hcy levels of observation group were lower than those of the control group,the serum APN level was higher than that of the control group (P ＜ 0.05);the incidence of gestational hypertension,hydramnios,cesarean section and premature delivery of observation group was significantly lower than that of the control group (P ＜0.05);the incidence of giant child,neonatal Jaundice and neonatal respiratory distress in the observation group was significantly lower than that of the control group (P＜0.05).Conclusion:Metformin combined with Jinlida granules was effective for the gestational diabetes mellitus,which could effectively control the blood glucose,blood lipid levels and might be related to the regulation of serum VEGF,APN and Hey levels.
ABSTRACT
Objective To observe the effect of Tongxinluo capsule combined with Jinlidas intervention on vascular endothelial fuction and blood glucose in the patients with Type 2 diabetes. Methods A total of 100 patients with Type 2 diabetes were randomly divided into treatment and control groups with 50 patients each. Both groups were received subcutaneous injection insulin, oral admistration of Simvastatin and Aspirin. And the treatment group were received Tongxinluo capsule and Jinlida sintervention based on the standard treatment. The changes of serum levels of FPG, 2hPG, HbAlc, VEGF, NO, ET-1 were observed before and after treatement. All the patients were treated for 12 weeks. Results After the treatment, the serum of FPG (7.03 ± 2.11 mmol/L vs. 8.09 ± 2.03 mmol/L, t=1.911), 2hPG (9.27 ± 2.03 mmol/L vs. 12.06 ± 3.54 mmol/L, t=1.946), HbAlc (6.98%± 1.58%vs. 8.06% ± 2.13%, t=2.013) were decreasd (P<0.05). Besides, VEGF (684.61 ± 84.37 ng/L vs. 514.28 ± 79.52 ng/L, t=2.136), NO (43.28 ± 6.40 ng/L vs. 34.64 ± 6.70 ng/L, t=2.097) of treatment group were siginificantly higher than the control group (P<0.05), while ET-1 (53.13 ± 7.24μmol/L vs. 60.09 ± 7.18μmol/L, t=2.271) were siginificantly lower (P<0.05). Conclusion Tongxinluo capsule combined with Jinlida sintervention could decreased the level Blood glucose and improve vascular endothelial fuction in the patients with Type 2 diabetes.
ABSTRACT
Objective To explore the protective effect of Jinlida granuleson kidney tissues of type 1 diabetic rats, and to elucidate the related mechanism. Methods SD rats were intraperitoneally injected with streptozotocin (STZ, 60 mg/kg) to establish type 1 diabetic models. Then the model rats were randomly divided into diabetic model group, low-, medium- and high-dose Jinlida groups (0. 75, 1. 5 and 3. 0 g/kg Jinlida granules, respectively), Jinlida + Tongxinluo (TXL) group (1. 5 g/kg Jinlida granules+ 0. 4 g/kg TXL), metformin group (50 mg/kg metformin), and saxagliptin group (1 mg/kg saxagliptin), with each group containing 5 rats. Five healthy rats served as normal controls. Eight weeks after administration of drugs or placebo, the levels of growth hormone (GH), growth hormone receptor (GHR), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 1 receptor (IGF-1R), and insulin-like growth factor lbinding protein 1 (IGFBP-1) mRNA were detected by real-time quantitative PCR, the expressions of MAPK pathway related proteins and fibronectin (FN) were determined by Western blotting; and H-E staining, Masson staining and PAS staining were used to observe the morphological changes of kidney tissues. Results Compared with the normal control group, the levels of GH, GHR, IGF-1, IGF-1R mRNA and the protein expressions of p-ERK, p-JNK, and FN of kidney tissues were significantly increased (P<0. 01), with cellular proliferation and fibrous deposition seen in the kidney tissues in the diabetic model group. After intervention with midde and high-dose Jinhda granules, the levels of GH, GHR, IGF-1, and IGF-1R mRNA and ratios of p-ERK/ERK, p-JNK/JNK, and FN protein expression were significantly decreased (P<0. 05, P<0. 01), with alleviated kidney tissues fibrosis. Conclusion Jinlida granules can protett kidney tissues of type 1 diabetic rats, which is probably through up-regulating the levels of GH and IGF-l mRNA and inhibiting the activation of the MAPK pathway.
ABSTRACT
Aim To investigate the effect of Jinlida on cholesterol-related genes in skeletal muscle in fat-in-duced insulin resistance ApoE-/ - mice. Methods Ten male C57 BL/6 J mice were selected as normal group ( NF );50 male ApoE-/ - mice with a high-fat feeding after 16 weeks ( HF) were divided into model group, rosiglitazone ( LGLT ) , Jinlida low dose group ( JLDL, 0. 95 g · kg-1 · d-1 ) , Jinlida medium dose group ( JLDM, 1. 9 g·kg-1 ·d-1 ) , Jinlida high dose group (JLDH, 3. 8 g·kg-1·d-1), which were per-formed intragastric administration for 8 weeks. Oil red O staining of mouse skeletal muscle was used for fat ac-cumulation. Insulin receptor ( INSR) , insulin receptor body substrate-1 ( IRS-1 ) , low-density lipoprotein re-ceptor ( LDLR ) , cholesterol sensor ( SCAP ) mRNA and protein expression in mouse skeletal muscle were measured by quantitative reverse transcription PCR ( RT-PCR ) and Western blot. Results Compared with NF group, fasting blood glucose ( FBG) , choles-terol ( TC ) , triglyceride ( TG ) and low density lipo-protein cholesterol ( LDL-C ) of HF mice were signifi-cantly elevated, while high-density lipoprotein ( HDL-C ) significantly decreased ( P < 0. 05 ) . Compared with HF group, Jinlida group could reduce to varying degrees FBG, TC, TG and LDL-C in mice, and in-crease HDL-C ( P <0. 05 ) . Jinlida could downgrade fasting serum insulin ( FINS ) level, and improve the insulin sensitive index ( ISI ) ( P < 0. 05 ) . Jinlida could obviously improve skeletal muscle fat accumula-tion of mice. Compared with NF group, skeletal mus-cle INSR, IRS-1, LDLR mRNA and protein levels of HF group were significantly decreased ( P <0. 05 ) , while SCAP mRNA and protein level increased signifi-cantly (P<0. 05). Compared with HF group, Jinlida could increase to varying degrees INSR, IRS-1, LDLR mRNA and protein levels ( P < 0. 05 ) , and lower SCAP mRNA and protein levels ( P<0. 05 ) . Conclu-sion Jinlida can alleviate fat-induced insulin resist-ance in ApoE-/ - mice through regulation of cholester-ol-related gene expression.
ABSTRACT
Objective: To investigate the protective effect of Jinlida granules on hippocampus of diabetic rats. Methods: Diabetic models were induced by high-fat diet and intraperitoneal injection of streptozotocin(STZ) in SD rats. The study was divided into diabetic model group, Jinlida granule groups(0. 75, 1. 5,and 3. 0 g/kg), α-lipoic acid group and insulin group. Healthy rats served as normal controls. Rats were tested in Morris water maze after 8 weeks of treatment, and then the hippocampus tissues were taken from each group and were infjected to TUNEL assay and transmission electron microscopy (TEM) observation. The activities of superoxide dismutase (SOD), glutathione (GSH), myeloperoxidase (MPO), and the contents of malondialdehyde (MDA) were all examined. Results: The diabetic rats developed studying and memory disorders 8 weeks after establishment. Except for those in the low-dose Jinlida group, rats in other treatment groups had improved studying and memory functions to different extents. Compared with normal control group, rats in the model group had more apoptotic neurons in the hippocampal CA1 area, prominent ultrastructure damage, significantly decreased SOD and GSH activities (P<0. 05), and significantly increased MPO activity and MDA level (P<0. 05). Compared with the model group, rats in all the treatment groups had decreased apoptosis and less ultrastructure damage;and rats in high-dose Jinlida group, α-lipoic acid group and insulin group had significantly increased SOD and GSH activities and significantly decreased MPO activity in the hippocampal CA1 area (P<0. 05); and the high-dose Jinlida granule group had a similar effect to α-lipoic acid group. Conclusion: Jinlida granule can protect the hippocampus of diabetic rats.
ABSTRACT
Objective To evaluate the effects of Jinlida granules on the renin-angiotensin system (RAS) in the kidney, heart and abdominal aorta of experimental diabetic rats, so as to explore the possible mechanism by which Jinlida granules protect the kidney and cardiovascular system. Methods The rats were randomized into 2 groups: normal contronl group (CON group, n=10) and diabetic model group Cn = 20). Rats in the control group were fed with regular chow; those in the diabetic model group were fed with high-fat diet for 4 weeks, and then were administered with streptozotocin (STZ; 30 mg/kg) by intraperitoneal injection to induce diabetic model. Successful diabetic models were further randomized into two groups with 10 in each; Jinlida granules treatment group (DM + JLG group) and non-treatment group (DM group). Rats in DM + JLG group were given Jinlida granules orally (3 g/kg per day) for 8 weeks. Angiotensin I (Ang I) and angiotensin P (Ang II) were measured by enzyme-linked immunosorbent assay (ELISA) in the homogenates of the kidney, heart and abdominal aortas the protein expression of angiotensin II type 1 receptor (ATR) and angiotensin II type 2 receptor (AT2R) was detected by Western blotting analysis. Results Compared with CON group, the kidney mass/body mass(KM/BM), heart mass/body mass (HM/BM), blood glucose (BG), and 24-hour urine proteins (24 h UP) were significantly increased in the DM group (P
ABSTRACT
Objective to investigate the protective effect of Jinlida granules on islet β cells in diabetes mellitus rats. Methods Diabetic models were induced by high-fat diet and intraperitoneal injection of streptozotocin (STZ) in SD rats. The study was divided into model group, Jinlida granule group (0.75, 1.5, 3.0g/kg) α-lipoic acid group, insulin group, and metformin group. Each group was given corresponding drugs, with insulin given by subcutaneous injection and other drugs given by intragastric administration. The body weight, fasting blood glucose (FBG), fasting insulin (FINS), glycosylated hemoglobin (HbAlc), the activities of super oxide dismutase (SOD) and glutathione (GSH), and the contents of malondialdehyde(MDA), IL-10 and TNF-« were examined 2 months later. The pancreatic tissues were immunostained for insulin. Results Compared with the model group, the levels of FBG and HbAlc were decreased in other groups (P<0. 05, P< 0. 01). The activities of SOD and GSH were significantly increased (P<0. 01) and the levels of MDA, IL-1β and TNF-α were significantly decreased (P<0. 01) In high-dose (3. 0 g/kg) Jinlida granule group, with increased islet area as shown by pathological staining. Conclusion Jinlida granule has protective effect against STZ-induced islet β cell injury in diabetic rats.
ABSTRACT
Objective To evaluate the effects of Jinlida granules on the renin-angiotensin system (RAS) in the kidney, heart and abdominal aorta of experimental diabetic rats, so as to explore the possible mechanism by which Jinlida granules protect the kidney and cardiovascular system. Methods The rats were randomized into 2 groups: normal contronl group (CON group, n=10) and diabetic model group Cn = 20). Rats in the control group were fed with regular chow; those in the diabetic model group were fed with high-fat diet for 4 weeks, and then were administered with streptozotocin (STZ; 30 mg/kg) by intraperitoneal injection to induce diabetic model. Successful diabetic models were further randomized into two groups with 10 in each; Jinlida granules treatment group (DM + JLG group) and non-treatment group (DM group). Rats in DM + JLG group were given Jinlida granules orally (3 g/kg per day) for 8 weeks. Angiotensin I (Ang I) and angiotensin P (Ang II) were measured by enzyme-linked immunosorbent assay (ELISA) in the homogenates of the kidney, heart and abdominal aortas the protein expression of angiotensin II type 1 receptor (ATR) and angiotensin II type 2 receptor (AT2R) was detected by Western blotting analysis. Results Compared with CON group, the kidney mass/body mass(KM/BM), heart mass/body mass (HM/BM), blood glucose (BG), and 24-hour urine proteins (24 h UP) were significantly increased in the DM group (P
ABSTRACT
AIM:To observe the influence of the different bore diameter ceramic membranes on the processing parameters of Jinlida Granules(Radix et Rhizoma Salviae miltiorrhizae,Radix Sophorae flavescentis,Rhizoma Polygonati,etc.) and optimize the process of membrane filtration. METHODS: Three different membranes were tested to observe the changes in membrane flux and the content of effective components by Jinlida Granules extract. RESULTS: The 50 nm membrane had the great flux,the transfer rates of matrine and salvianolic acid were the highest;The optimum conditions: the operation differential pressure was 0.08～0.12MPa;the operation temperature was 50～60℃;the membrane surface flow rate was 3.0 m/s.When the volume of filtration solution was condensed to one tenth,adding the same volume aeionized water,and the effective components transfer rate reached 80%.Using the strong acid and strong alkali to wash it in turn,the flux can revivify above 90%. CONCLUSION: Applying the ceramic membrane to ultrafiltrate Jinlida Granule is good and useful to herb purification.